<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Aripiprazole for autism spectrum disorders (ASD) - Hirsch, LE - 2016 | Cochrane Library</title> <meta content="Aripiprazole for autism spectrum disorders (ASD) - Hirsch, LE - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009043.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Aripiprazole for autism spectrum disorders (ASD) - Hirsch, LE - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009043.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009043.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Aripiprazole for autism spectrum disorders (ASD)" name="citation_title"/> <meta content="Lauren E Hirsch" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="Tamara Pringsheim" name="citation_author"/> <meta content="University of Calgary" name="citation_author_institution"/> <meta content="tmprings@ucalgary.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD009043.pub3" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/06/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009043.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009043.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009043.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antipsychotic Agents [*therapeutic use]; Aripiprazole [*therapeutic use]; Child Development Disorders, Pervasive [*drug therapy]; Hyperkinesis [drug therapy]; Irritable Mood [drug effects]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009043.pub3&amp;doi=10.1002/14651858.CD009043.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="z6k50IFd";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009043\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009043\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","ta","ms","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009043.pub3",title:"Aripiprazole for autism spectrum disorders (ASD)",firstPublishedDate:"Jun 26, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009043.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009043.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009043.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009043.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009043.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009043.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009043.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009043.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009043.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009043.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13850 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009043.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0112"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0030"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0031"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0065"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-sec-0106"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/appendices#CD009043-sec-0117"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/table_n/CD009043StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/table_n/CD009043StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Aripiprazole for autism spectrum disorders (ASD)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information#CD009043-cr-0002">Lauren E Hirsch</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information#CD009043-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Tamara Pringsheim</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information/en#CD009043-sec-0137">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 June 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009043.pub3">https://doi.org/10.1002/14651858.CD009043.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009043-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009043-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009043-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009043-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009043-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009043-abs-0001" lang="en"> <section id="CD009043-sec-0001"> <h3 class="title" id="CD009043-sec-0001">Background</h3> <p>Autism spectrum disorders (ASD) include autistic disorder, Asperger's disorder and pervasive developmental disorder ‐ not otherwise specified (PDD‐NOS). Antipsychotics have been used as a medication intervention for irritability related to ASD. Aripiprazole, a third‐generation, atypical antipsychotic, is a relatively new drug that has a unique mechanism of action different from that of other antipsychotics. This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD, published in 2011 (Ching 2011). </p> </section> <section id="CD009043-sec-0002"> <h3 class="title" id="CD009043-sec-0002">Objectives</h3> <p>To assess the safety and efficacy of aripiprazole as medication treatment for individuals with ASD. </p> </section> <section id="CD009043-sec-0003"> <h3 class="title" id="CD009043-sec-0003">Search methods</h3> <p>In October 2015, we searched the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL) and seven other databases as well as two trial registers. We searched for records published in 1990 or later, as this was the year aripiprazole became available. </p> </section> <section id="CD009043-sec-0004"> <h3 class="title" id="CD009043-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) of aripiprazole (administered orally and at any dosage) versus placebo for treatment of individuals with a diagnosis of ASD. </p> </section> <section id="CD009043-sec-0005"> <h3 class="title" id="CD009043-sec-0005">Data collection and analysis</h3> <p>Two review authors independently collected, evaluated and analysed data. We performed meta‐analysis for primary and secondary outcomes, when possible. We used the GRADE (<b>G</b> rades of <b>R</b> ecommendation, <b>A</b> ssessment, <b>D</b> evelopment and <b>E</b>valuation) approach to rate the overall quality of the evidence. </p> </section> <section id="CD009043-sec-0006"> <h3 class="title" id="CD009043-sec-0006">Main results</h3> <p>We included three trials in this review. Two were included in the previous published review, and the results of one, placebo‐controlled discontinuation study were added to this review. Although we searched for studies across age groups, we found only studies conducted in children and youth. Included trials had low risk of bias across most domains. High risk of bias was seen in only one trial with incomplete outcome data. We judged the overall quality of the evidence for most outcomes to be moderate. </p> <p>Two RCTs with similar methods evaluated use of aripiprazole for a duration of eight weeks in 316 children/adolescents with ASD. Meta‐analysis of study results revealed a mean improvement of ‐6.17 points on the Aberrant Behavior Checklist (ABC) ‐ Irritability subscale (95% confidence intervals (CIs) ‐9.07 to ‐3.26, two studies, 308 children/adolescents, moderate‐quality evidence), ‐7.93 points on the ABC ‐ Hyperactivity subscale (95% CI ‐10.98 to ‐4.88, two studies, 308 children/adolescents, moderate‐quality evidence) and ‐2.66 points on the ABC ‐ Stereotypy subscale (95% CI ‐3.55 to ‐1.77, two studies, 308 children/adolescents, moderate‐quality evidence) in children/adolescents taking aripiprazole relative to children/adolescents taking placebo. In terms of side effects, children/adolescents taking aripiprazole had a greater increase in weight, with a mean increase of 1.13 kg relative to placebo (95% CI 0.71 to 1.54, two studies, 308 children/adolescents, moderate‐quality evidence), and had a higher risk ratio (RR) for sedation (RR 4.28, 95% CI 1.58 to 11.60, two studies, 313 children/adolescents, moderate‐quality evidence) and tremor (RR 10.26, 95% CI 1.37 to 76.63, two studies, 313 children/adolescents, moderate‐quality evidence). A randomised, placebo‐controlled discontinuation study found that 35% of children/adolescents randomised to continue intervention with aripiprazole relapsed with respect to their symptoms of irritability, compared with 52% of children/adolescents randomised to placebo, for a hazard ratio of 0.57 (95% CI 0.28 to 1.12, 85 children/adolescents, low‐quality evidence). </p> <p>All three included trials were supported by Bristol‐Myers Squibb (Princeton, NJ) and Otsuka Pharmaceutical Company, Ltd. (Tokyo, Japan), with editorial support provided by Ogilvy Healthworld Medical Education and Bristol‐Myers Squibb. </p> </section> <section id="CD009043-sec-0007"> <h3 class="title" id="CD009043-sec-0007">Authors' conclusions</h3> <p>Evidence from two RCTs suggests that aripiprazole can be effective as a short‐term medication intervention for some behavioural aspects of ASD in children/adolescents. After a short‐term medication intervention with aripiprazole, children/adolescents showed less irritability and hyperactivity and fewer stereotypies (repetitive, purposeless actions). However, notable side effects, such as weight gain, sedation, drooling and tremor, must be considered. One long‐term, placebo discontinuation study found that relapse rates did not differ between children/adolescents randomised to continue aripiprazole versus children/adolescents randomised to receive placebo, suggesting that re‐evaluation of aripiprazole use after a period of stabilisation in irritability symptoms is warranted. Studies included in this review used criteria from the <i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition</i> (DSM‐IV) (<a href="http://APA 2000" target="_blank">APA 2000</a>) for ASD diagnosis; however, the diagnostic criteria for ASD changed significantly with release of the fifth edition of the DSM (DSM‐5) in 2013 (<a href="http://APA 2013" target="_blank">APA 2013</a>). </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009043-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009043-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009043-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009043-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009043-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009043-abs-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009043-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ta#CD009043-abs-0006">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009043-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009043-abs-0003" lang="en"> <h3>Aripiprazole for autism spectrum disorders (ASD)</h3> <p><b>Background</b> </p> <p>Aripirazole is an antipsychotic drug ‐ a type of medication used to treat serious mental disorders such as paranoia. It has also been used to treat behavioural problems (e.g. aggression, severe temper tantrums) in people with autism spectrum disorders (ASD). Aripiprazole has been shown to be well tolerated and to improve behavioural problems in other disorders such as schizophrenia and bipolar disorder. As aripiprazole is a relatively new drug, it is important to understand both the benefits and side effects of this drug in patients with ASD. </p> <p><b>Review question</b> </p> <p>Do children and adults with ASD benefit from treatment with aripiprazole, compared with other children and adults with ASD who receive a drug with no active ingredient (placebo)? </p> <p><b>Study characteristics</b> </p> <p>In this review, we included three studies that investigated effects of aripiprazole. Two were short‐term (eight weeks) studies that evaluated whether aripiprazole improved behavioural problems in a total of 316 children/adolescents. The third was a longer‐term (up to 16 weeks) study in which 85 children/adolescents whose symptoms initially improved on aripiprazole discontinued the medication to evaluate whether their behavioural problems recurred. All participants were between six and 17 years of age. All studies used multiple behavioural checklists to assess symptoms of ASD. </p> <p><b>Key results and quality of evidence</b> </p> <p>Short‐term studies found improved irritability, hyperactivity and stereotypy (i.e. repetitive behaviours) and inappropriate speech in children/adolescents with ASD taking aripiprazole as compared with placebo. Researchers found no improvement in lethargy/withdrawal (i.e. lack of energy and reduced alertness). White children/adolescents were less likely to relapse (return to older, problematic behaviours) when taking aripiprazole, but this finding was not reported in children/adolescents of other races. Rates of movement disorder side effects such as tremor, muscle rigidity and involuntary movement were higher in children/adolescents taking aripiprazole in all trials. Results of this review suggest that short‐term use of aripiprazole may improve irritability, hyperactivity and repetitive movements in children/adolescents with ASD, although both weight gain and neurological side effects (e.g. involuntary movements of the face and jaw) can occur. Children and adolescents taking aripiprazole should be re‐evaluated periodically to monitor improvements in ASD symptoms and side effects. Overall, the quality of this evidence is moderate. Since the time these studies were conducted, an updated version of the manual for diagnosing ASD and other conditions has been published. Additional studies evaluating safety and benefits of long‐term use of aripiprazole would be helpful. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009043-sec-0112" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009043-sec-0112"></div> <h3 class="title" id="CD009043-sec-0113">Implications for practice</h3> <section id="CD009043-sec-0113"> <p>Evidence from this review shows that use of aripiprazole for the short‐term treatment of irritability in children/adolescents with ASD may be worth considering. If the decision is made to use aripiprazole, clinicians should follow established best practice and provide information about side effects such as weight gain, tremor, drooling and sedation to children/adolescents and their families, so they can consider the benefits and risks of treatment before commencing a medication trial. Children/adolescents undergoing a trial of therapy with aripiprazole should be monitored for clinical effectiveness of the medication, as well as for side effects. In the absence of high‐quality evidence, and given that similar relapse rates are observed for both aripiprazole and placebo, evidence suggests that the use of aripiprazole should be re‐evaluated periodically for continued efficacy, and that it might be appropriate to consider discontinuation of aripiprazole after successful treatment for 12 weeks. </p> </section> <h3 class="title" id="CD009043-sec-0114">Implications for research</h3> <section id="CD009043-sec-0114"> <p>Additional trials should be conducted to investigate use of aripiprazole versus placebo for longer than three months. Only one trial compared aripiprazole head‐to‐head with another medication, risperidone. Future trials comparing aripiprazole versus other medications should be conducted to improve our understanding of the efficacy and safety of aripiprazole relative to other pharmacological interventions. Trials of these medications in older individuals with continuing symptoms should also be performed. Furthermore, trials that use behavioural interventions as a first‐line approach and medication interventions as an adjunct should be performed. Future reviews should include health‐related quality of life as an outcome measure. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009043-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009043-sec-0022"></div> <div class="table" id="CD009043-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Aripiprazole compared with placebo for autism spectrum disorders (ASD)*</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children/youth with ASD </p> <p><b>Settings:</b> ambulatory care </p> <p><b>Intervention:</b> aripiprazole </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect (95% confidence interval)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ABC ‐ Irritability subscale</b> </p> <p>Mean score changes</p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐6.17 (‐9.07 to ‐3.26) points relative to placebo, in favour of aripiprazole</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ABC ‐ Hyperactivity subscale</b> </p> <p>Mean score changes</p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐7.93 (‐10.98 to ‐4.88) points relative to placebo, in favour of aripiprazole</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ABC ‐ Stereotypy subscale</b> </p> <p>Mean score changes</p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.66 (‐3.55 to ‐1.77) points relative to placebo, in favour of aripiprazole</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight gain</b> </p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.13 (0.71 to 1.54) points relative to placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation</b> </p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 4.28 (1.58 to 11.60)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tremor</b> </p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 10.26 (1.37 to 76.63)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse rate</b> </p> <p>16 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>HR 0.57 (0.28 to 1.12)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85</p> <p>(1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ABC:</b> Aberrant Behavior Checklist; <b>GRADE:</b> Grades of Recommendation, Assessment, Development and Evaluation; <b>HR:</b> hazard ratio;<b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Quality was rated as moderate because of unclear risk of bias for some domains in <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, and because of the overall small number of studies conducted using aripiprazole in ASD.<br/> <sup>b</sup>Quality of evidence for long‐term trials was rated as low because of high risk of attrition bias for incomplete outcome data in <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>. Further research may have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p>*A small number of studies have evaluated the use of aripiprazole for ASD. Only one study examined aripiprazole at a duration longer than eight weeks. Future trials of aripiprazole in children/adolescents with ASD are likely to impact the estimates found in this review. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009043-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009043-sec-0023"></div> <section id="CD009043-sec-0024"> <h3 class="title" id="CD009043-sec-0024">Description of the condition</h3> <p>Before 2013, autism spectrum disorders (ASD) represented pervasive developmental disorders of variable severity, defined as autistic disorder, Asperger's disorder and pervasive developmental disorder ‐ not otherwise specified (PDD‐NOS) in the <i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition ‐ Text Revision</i> (DSM‐IV‐TR) (<a href="./references#CD009043-bbs2-0023" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 2000. ">APA 2000</a>), and as childhood autism, atypical autism, Rett's syndrome, other childhood disintegrative disorder, Asperger's syndrome, other pervasive developmental disorder and pervasive developmental disorder unspecified in the <i>International Statistical Classification of Diseases and Related Health Problems, Tenth Edition</i> (ICD‐10) (<a href="./references#CD009043-bbs2-0060" title="World Health Organization. International Statistical Classification of Diseases and Related Health Problems, 10th Revision. Vol. 1‐3, Geneva: World Health Organization, 1994. ">WHO 1994</a>). The three characteristic manifestations of ASD are (1) impaired social interaction, (2) impaired communication and (3) restricted repetitive and stereotyped patterns of behaviour. Diagnostic criteria for ASD changed significantly with the release of the fifth edition of the DSM (DSM‐5) in 2013 (<a href="./references#CD009043-bbs2-0024" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. Arlington, VA: American Psyciatric Publishing, 2013. ">APA 2013</a>). Autistic disorder, Asperger's disorder and PDD‐NOS were collapsed into a single diagnosis of ASD ‐ a single diagnosis with considerable diagnostic variability. The social and communication domains of ASD were combined, leaving two key symptom domains: (1) social communication and (2) restricted and repetitive behaviours. </p> <p>As a result of symptom variability, clinicians are encouraged to describe diagnostic specifics in detail, in particular, intelligence and speech and language level. Kanner first described autism in 1943 through his observations of several afflicted children, noting their affinity for extreme aloneness and sameness, and their inability to form purposeful relationships with other people (<a href="./references#CD009043-bbs2-0045" title="KannerL . Autistic disturbances of affective contact. Nervous Child1943;2:217‐50. ">Kanner 1943</a>). Secondary characteristics, such as emotional and behavioural problems, are extremely common; examples of these include irritability, aggression, poor temper, self injury and injury to others (<a href="./references#CD009043-bbs2-0048" title="LecavalierL . Behavioral and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. Journal of Autism and Developmental Disorders2006;36(8):1101‐14. [PUBMED: 16897387] ">Lecavalier 2006</a>). As no biomarkers have been established, the diagnosis of ASD is based on behavioural features. </p> <p>Autism spectrum disorder is a lifelong condition. Individuals with ASD are frequently affected by other neuropsychiatric conditions as well, the most common of which are attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder (ODD) and anxiety disorders (<a href="./references#CD009043-bbs2-0055" title="SimonoffE , PicklesA , CharmanT , ChandlerS , LoucasT , BairdG . Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity and associated factors in a population derived sample. Journal of the American Academy of Child and Adolescent Psychiatry2008;47(8):921‐9. [PUBMED: 18645422] ">Simonoff 2008</a>). Autism spectrum disorder is a neurodevelopmental disorder, but the exact genetic and environmental factors contributing to its cause are unknown. Boys are three to four times more likely to have ASD than girls, again suggesting the importance of genetics in the disorder. </p> <p>Estimates of the prevalence of ASD vary. A systematic review of prevalence studies of ASD from 1966 to 2004 identified an overall estimate of prevalence of 7.1 per 10,000 for autism (95% confidence interval (CI) 1.6 to 30.6) and 20 per 10,000 (95% CI 4.9 to 82.1) for all ASD (<a href="./references#CD009043-bbs2-0061" title="WilliamsJG , HigginsJP , BrayneCE . Systematic review of prevalence studies of autism spectrum disorders. Archives of Diseases in Childhood2006;91(1):8‐15. [PUBMED: 15863467] ">Williams 2006</a>). Variation in the prevalence estimate of typical autism has been significantly affected by the diagnostic criteria used, the age of children screened and study location. More recent prevalence studies have yielded higher estimates. The 2007 National Survey of Children's Health (N (sample size) = 78,037) found the weighted ASD point prevalence to be 110 per 10,000 in the United States (<a href="./references#CD009043-bbs2-0046" title="KoganMD , BlumbergSJ , SchieveLA , BoyleCA , PerrinJM , GhandourRM , et al. Prevalence of parent‐reported diagnosis of autism spectrum disorders among children in the US, 2007. Pediatrics2009;124(5):1395‐403. ">Kogan 2009</a>). In a UK school‐based population study in the Special Educational Needs register, the prevalence estimate for ASD was 94 per 10,000 (<a href="./references#CD009043-bbs2-0026" title="Baron‐CohenS , ScottFJ , AllisonC , WilliamsJ , BoltonP , MatthewsFE , et al. Prevalence of autism spectrum conditions: UK school based population study. British Journal of Psychiatry2009;194(6):500‐9. ">Baron‐Cohen 2009</a>). Most recently, a 2014 report by the Centers for Disease Control and Prevention (CDC) found the point prevalence of ASD to be 14.7 per 1000 eight‐year‐olds (<a href="./references#CD009043-bbs2-0030" title="Centers for Disease Control and Prevention. Community Report from the Autism and Developmental Disabilities Monitoring (ADDM) Network: a snapshot of autism spectrum disorder among 8‐year‐old children in multiple communities across the United States in 2010. http://www.cdc.gov/ncbddd/autism/documents/community_report_autism.pdf (accessed 4 September 2015). ">CDC 2014</a>). A systematic review found that the median worldwide prevalence of autistic disorder was 17 per 100,000, with a range of 2.8 to 94 per 100,000; the median worldwide prevalence of pervasive developmental disorder was 62 per 100,000, with a range of 1 to 189 per 100,00 (<a href="./references#CD009043-bbs2-0033" title="ElsabbaghM , DivanG , KohY , KimYS , KauchaliS , MarcinC , et al. Global prevalence of autism and other pervasive developmental disorders. Autism Research2012;5(3):160‐79. [PUBMED: 22495912] ">Elsabbagh 2012</a>). </p> <p>Both pharmacological and non‐pharmacological interventions are available for children and adults with ASD. Non‐pharmacological interventions include educational, behavioural and social communication strategies that are used alone or in combination as part of an individual plan to enhance learning and community participation. These interventions strive to improve communication, social skills, daily living skills, play and leisure skills, academic achievement and maladaptive behaviours (<a href="./references#CD009043-bbs2-0050" title="MyersS , JohnsonC , Council on Children with Disabilities. Management of children with autism spectrum disorders. Pediatrics2007;120(5):1162‐82. ">Meyers 2007</a>). </p> </section> <section id="CD009043-sec-0025"> <h3 class="title" id="CD009043-sec-0025">Description of the intervention</h3> <p>Aripiprazole is a novel, atypical, antipsychotic drug with distinct mechanisms of action through its receptor binding profile. Typical antipsychotic medications, such as haloperidol, are potent antagonists at D<sub>₂</sub>‐dopamine receptors. Second‐generation antipsychotics, such as risperidone, are high‐affinity antagonists at D<sub>₂</sub>‐dopamine receptors and serotonin 5‐HT<sub>₂A</sub> receptors. Aripiprazole has functionally significant interactions at D<sub>₂</sub>, D<sub>₃</sub> and D<sub>₄</sub> dopamine receptors, and at 5‐HT<sub>₁A</sub>, 5‐HT<sub>₂A</sub>, 5‐HT<sub>₂B</sub>, 5‐HT<sub>₂C</sub>, 5‐HT<sub>₆</sub> and 5‐HT<sub>₇</sub> serotonin receptors. Aripiprazole is postulated to work by being a dopamine‐serotonin partial agonist, or by working through the mechanism of functional selectivity, whereby D<sub>₂</sub> functional effects are dependent on the cellular location of the D<sub>₂</sub> receptor (<a href="./references#CD009043-bbs2-0054" title="ShapiroDA , RenockS , ArringtonE , ChiodoLA , LiuLX , SibleyDR , et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology2003;28(8):1400‐11. [PUBMED: 12784105] ">Shapiro 2003</a>). The functional selectivity hypothesis proposes that depending upon the cellular milieu, a mixture of agonist, partial agonist and antagonist actions is likely. Thus, the unique and robust mechanism of aripiprazole lies in its ability to be a dopamine agonist when levels are too low, and a dopamine antagonist when levels are too high (<a href="./references#CD009043-bbs2-0038" title="GoodnickPJ , JerryJM . Aripiprazole: profile on efficacy and safety. Expert Opinion on Pharmacotherapy2002;3(12):1773‐81. [PUBMED: 12472374] ">Goodnick 2002</a>). </p> <section id="CD009043-sec-0026"> <h4 class="title">What is known about other antipsychotic medications in ASD?</h4> <p>Both typical (first‐generation) and atypical (second‐generation) antipsychotics have been evaluated for the treatment of behavioural symptoms in individuals with ASD. Although short‐term randomised controlled trials (RCTs) suggest efficacy for improving some symptoms of ASD, important side effects limit their use. Typical antipsychotics have been associated with drug‐induced movement disorders. Haloperidol, for example, has been evaluated for the treatment of ASD in several trials and has been associated with improvements in withdrawal and stereotypies (<a href="./references#CD009043-bbs2-0022" title="AndersonLT , CampbellM , AdamsP , SmallAM , PerryR , ShellJ . The effects of haloperidol on discrimination learning and behavioural symptoms in autistic children. Journal of Autism and Developmental Disorders1989;19(2):227‐39. ">Anderson 1989</a>), as well as positive effects on learning (<a href="./references#CD009043-bbs2-0028" title="CampbellM , AndersonLT , SmallAM , PerryR , GreenWH , CaplanR . The effects of haloperidol on learning and behaviour in autistic children. Journal of Autism and Developmental Disorders1982;12(2):167‐75. [PUBMED: 7174605] ">Campbell 1982</a>); however, it has also been associated with extrapyramidal side effects such as acute dystonic reactions, withdrawal dyskinesias and tardive dyskinesia in this population (<a href="./references#CD009043-bbs2-0029" title="CampbellM , ArmenterosJL , MaloneRP , AdamsPB , EisenbergZW , OverallJE . Neuroleptic‐related dyskinesias in autistic children: a prospective, longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):835‐43. [PUBMED: 9183140] ">Campbell 1997</a>). A systematic review of risperidone for ASD demonstrated efficacy of this medication in treating symptoms of aggression, irritability and repetitive behaviour; notable side effects included weight gain, increased appetite and sedation (<a href="./references#CD009043-bbs2-0044" title="JesnerOS , Aref‐AdibM , CorenE . Risperidone for autism spectrum disorder. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD005040.pub2] ">Jesner 2009</a>) . </p> </section> </section> <section id="CD009043-sec-0027"> <h3 class="title" id="CD009043-sec-0027">How the intervention might work</h3> <p>Alterations in dopaminergic and serotonergic neurotransmission have been implicated in ASD, and abnormalities in these systems have been demonstrated through neuroimaging and metabolic studies (<a href="./references#CD009043-bbs2-0051" title="PoseyDJ , StiglerSKA , EricksonCA , McDougleCJ . Antipsychotics in the treatment of autism. Journal of Clinical Investigation2008;118(1):6‐14. ">Posey 2008</a>). As aripiprazole has affinity for both dopamine and serotonin receptors, it is likely to exert its action through mechanisms similar to those of other antipsychotic medications. When compared, the 5‐HT<sub>₂</sub> antagonism of aripiprazole is higher than most atypical antipsychotics but lower than ziprasidone or risperidone; however its degree of antagonist activity, along with partial D<sub>₂</sub> agonist activity, is at an optimal level, reducing the risk of extrapyramidal signs such as tardive dyskinesia (<a href="./references#CD009043-bbs2-0038" title="GoodnickPJ , JerryJM . Aripiprazole: profile on efficacy and safety. Expert Opinion on Pharmacotherapy2002;3(12):1773‐81. [PUBMED: 12472374] ">Goodnick 2002</a>). Aripiprazole has moderate H<sub>₁</sub> receptor affinity, which results in decreased sedation and risk of weight gain, compared with clozapine and olanzapine, which have high affinities at this receptor (<a href="./references#CD009043-bbs2-0038" title="GoodnickPJ , JerryJM . Aripiprazole: profile on efficacy and safety. Expert Opinion on Pharmacotherapy2002;3(12):1773‐81. [PUBMED: 12472374] ">Goodnick 2002</a>). </p> <section id="CD009043-sec-0028"> <h4 class="title">Aripiprazole use in other disorders</h4> <p>Aripiprazole has been shown in a placebo‐controlled trial to be an effective intervention for positive and negative symptoms of schizophrenia, with a lower propensity to induce certain movement disorders, weight gain or sedation, or to increase cholesterol and prolactin levels, compared with drugs such as olanzapine or risperidone (<a href="./references#CD009043-bbs2-0047" title="KomossaK , Rummel‐KlugeC , SchmidF , HungerH , SchwarzS , El‐SayehHGG , et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD006569.pub3] ">Komossa 2009</a>). Studies have shown that antipsychotic medications can cause increased weight gain and increased risk of type 2 diabetes in children and adolescents (<a href="./references#CD009043-bbs2-0027" title="BoboWV , CooperWO , SteinCM , OlfsonM , GrahamD , DaughertyJ , et al. Antipsychotics and the risk of type 2 diabetes mellitus in children and youth. JAMA Psychiatry2013;70(10):1067‐75. [PUBMED: 23965896] ">Bobo 2013</a>; <a href="./references#CD009043-bbs2-0031" title="CorrellCU , ManuP , OlshanskiyV , NapolitanoB , KaneJM , MalhotraAK . Cardiometabolic risk of second‐generation antipsychotic medications during first‐time use in children and adolescents. JAMA2009;302(16):1765‐73. [PUBMED: 19861668] ">Correll 2009</a>). Aripiprazole was well tolerated in a placebo‐controlled trial of adolescents with schizophrenia, causing few side effects (<a href="./references#CD009043-bbs2-0035" title="FindlingRL , RobbA , NyilasM , ForbesRA , JinN , IvanovaS , et al. A multiple‐center, randomized, double‐blind, placebo‐controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. American Journal of Psychiatry2008;165(11):1432‐41. [PUBMED: 18765484] ">Findling 2008</a>). Another placebo‐controlled trial has shown its efficacy and tolerability in treating adolescents with bipolar I disorder or mixed episodes, with no significant weight changes compared with placebo (<a href="./references#CD009043-bbs2-0036" title="FindlingRL , NyilasM , ForbesRA , McQuadeRD , JinN , IwamotoT , et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2009;70(10):1441‐51. [PUBMED: 19906348] ">Findling 2009</a>). The half‐life of aripiprazole of 72 hours allows once‐daily dosing and increased assurance of full absorption (<a href="./references#CD009043-bbs2-0038" title="GoodnickPJ , JerryJM . Aripiprazole: profile on efficacy and safety. Expert Opinion on Pharmacotherapy2002;3(12):1773‐81. [PUBMED: 12472374] ">Goodnick 2002</a>). </p> </section> </section> <section id="CD009043-sec-0029"> <h3 class="title" id="CD009043-sec-0029">Why it is important to do this review</h3> <p>This review updates a previous Cochrane review on the safety and efficacy of aripiprazole for individuals with ASD published in 2011 (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>). Aripiprazole currently has United States (US) Food and Drug Administration (FDA)‐labelled indications for the treatment of schizophrenia, bipolar disorder, major depressive disorder and autistic disorder (<a href="./references#CD009043-bbs2-0034" title="Food , DrugAdministration . Label and approval history: ability. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseraction=Search.Label_ApprovalHistory#apphist (accessed 28 February 2010). ">FDA 2010</a>). Although several antipsychotics have demonstrated benefit in the treatment of behavioural symptoms of ASD, all currently available medication interventions have side effects that limit their use. As aripiprazole is a relatively new drug, it is important to understand both the efficacy and the side effects of this intervention in individuals with ASD. It is also important to determine whether intervention effects are dependent on factors such as age, length of intervention or medication dosage. A synthesis of available data on aripiprazole in ASD will be useful for clinicians considering use of this agent for people with ASD. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009043-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009043-sec-0030"></div> <p>To assess the safety and efficacy of aripiprazole as medication treatment for individuals with ASD. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009043-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009043-sec-0031"></div> <section id="CD009043-sec-0032"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009043-sec-0033"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs), including both parallel‐group and cross‐over designs, of any duration. </p> </section> <section id="CD009043-sec-0034"> <h4 class="title">Types of participants</h4> <p>Children and adults with a clinical diagnosis of ASD made by an established classification system. Diagnosis of ASD includes individuals with autistic disorder, Asperger's disorder and pervasive developmental disorder ‐ not otherwise specified (PDD‐NOS). </p> <p>Diagnosis of ASD in trial participants was corroborated by administration of a standardised instrument such as the Autism Diagnostic Interview ‐ Revised (ADI‐R) (<a href="./references#CD009043-bbs2-0049" title="LordC , RutterM , LeCouteurA . Autism Diagnostic Interview ‐ Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. Journal of Autism and Developmental Disorders1994;24(5):659‐85. ">Lord 1994</a>). </p> <p>Given the high rate of co‐morbidity between ASD and other neuropsychiatric disorders, we did not exclude individuals with co‐morbid disorders. However, we did exclude participants receiving co‐interventions such as other antipsychotics, psychostimulants, antidepressants or mood stabilisers. We did not exclude participants receiving non‐pharmacological therapy (i.e. behaviour therapy) provided it was equally accessible to all study participants, stable before trial entry and consistent throughout the study. </p> </section> <section id="CD009043-sec-0035"> <h4 class="title">Types of interventions</h4> <p>Aripiprazole administered orally for ASD at any dosage compared with placebo.</p> </section> <section id="CD009043-sec-0036"> <h4 class="title">Types of outcome measures</h4> <section id="CD009043-sec-0037"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD009043-list-0001"> <li> <p>Emotional and behavioural symptoms, as measured by validated clinician‐ or parent‐reported scales. </p> <ul id="CD009043-list-0002"> <li> <p>Irritability (e.g. Aberrant Behaviour Checklist (ABC) ‐ Irritability subscale (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>)). </p> </li> <li> <p>Hyperactivity (e.g. ABC ‐ Hyperactivity subscale (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>)). </p> </li> <li> <p>Stereotypy (e.g. ABC ‐ Stereotypy subscale (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>)). </p> </li> <li> <p>Inappropriate speech (e.g. ABC ‐ Inappropriate Speech subscale (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>)). </p> </li> <li> <p>Lethargy/withdrawal (e.g. ABC ‐ Lethargy/Withdrawal subscale (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>)). </p> </li> <li> <p>Aggression (e.g. Overt Aggression Scale (OAS) (<a href="./references#CD009043-bbs2-0062" title="YudofskySC , SilverJM , JacksonW , EndicottJ , WilliamsD . The Overt Aggression Scale for the objective rating of verbal and physical aggression. American Journal of Psychiatry1986;143(1):35‐9. [PUBMED: 3942284] ">Yudofsky 1986</a>)). </p> </li> <li> <p>Clinical Improvement (e.g. Clinical Global Impression (CGI) ‐ Improvement scale (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>)). </p> </li> </ul> </li> <li> <p>Extrapyramidal side effects*, as measured by scales such as the modified Webster Scale (mWS) (<a href="./references#CD009043-bbs2-0059" title="WebsterDD . Critical analysis of the disability in Parkinson's disease. Modern Treatment1968;5(2):279‐81. [PUBMED: 5655944] ">Webster 1968</a>), the Abnormal Involuntary Movements Scale (AIMS) (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>) or the Barnes Akathisia Scale (BARS) (<a href="./references#CD009043-bbs2-0025" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. [PUBMED: 2574607] ">Barnes 1989</a>). </p> </li> </ul> </p> </section> <section id="CD009043-sec-0038"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009043-list-0003"> <li> <p>Obsessive‐compulsive behaviours as rated by, for example, the Children’s Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS) (<a href="./references#CD009043-bbs2-0037" title="GoodmanWK , PriceLH , RasmussenSA , MazureC , FleischmannRL , HillCL , et al. The Yale‐Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry1989;46(11):1006‐11. [PUBMED: 2684084] ">Goodman 1989</a>). </p> </li> <li> <p>Weight gain and metabolic side effects*.</p> </li> <li> <p>Other side effects*, for example, somnolence, insomnia, headache and constipation.</p> </li> </ul> </p> <p>We planned to synthesise results for the following time points: less than three months, three to six months and over six months. We were able to synthesise two trials that were eight weeks in duration and to describe, in detail, a discontinuation study of 16 weeks' duration. </p> <p>*Please note, we use the term 'side effects' to describe any harms, adverse effects or adverse drug reactions associated with aripiprazole. </p> </section> </section> </section> <section id="CD009043-sec-0039"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009043-sec-0040"> <h4 class="title">Electronic searches</h4> <p>Searches for the original review were run in May 2011. We limited the search to 1990 onwards, as this is the year in which aripiprazole first became available. We applied no language restrictions. We ran searches for this update in November 2014 and again in October 2015, using the search strategies presented in <a href="./appendices#CD009043-sec-0118">Appendix 1</a>. We have reported in <a href="./appendices#CD009043-sec-0133">Appendix 2</a> additional details about the searches, including exact search dates for each database. We searched the following databases. </p> <p> <ul id="CD009043-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 9; part of <i>The Cochrane Library</i>), which also contains the Cochrane Developmental, Psychosocial and Learning Problems Group Specialised Register. </p> </li> <li> <p>Ovid MEDLINE (1946 to October Week 1 2015).</p> </li> <li> <p>Embase (1980 to Week 41 2015; Ovid).</p> </li> <li> <p>CINAHL Plus (1937 to current; EBSCOhost).</p> </li> <li> <p>PsycINFO (1806 to October Week 1 2015; Ovid).</p> </li> <li> <p>Cochrane Database of Systematic Reviews (CDSR; 2015, Issue 10; <i>The Cochrane Library</i>). </p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE; 2015, Issue 2; <i>The Cochrane Library</i>). </p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science (CPCI‐S; 1990 to current; Web of Science).</p> </li> <li> <p><a href="http://www.autism.org.uk/autismdata" target="_blank">Autism Data</a> (all available years). </p> </li> <li> <p><a href="http://zetoc.mimas.ac.uk/" target="_blank">ZETOC</a> (limited to conference proceedings; all available years). </p> </li> <li> <p><a href="http://www.worldcat.org/" target="_blank">WorldCat</a> (limited to theses and dissertations; all available years). </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (all available years). </p> </li> <li> <p><a href="http://www.who.int/ictrp/en/" target="_blank">World Health Organisation International Clinical Trials Registry Platform</a> (WHO ICTRP; all available years). </p> </li> </ul> </p> </section> <section id="CD009043-sec-0041"> <h4 class="title">Searching other resources</h4> <p>We contacted the drug company that makes aripiprazole to determine whether any trials were ongoing or results unpublished in this area. </p> </section> </section> <section id="CD009043-sec-0042"> <h3 class="title" id="CD009043-sec-0042">Data collection and analysis</h3> <section id="CD009043-sec-0043"> <h4 class="title">Selection of studies</h4> <p>For the initial review, two review authors (TP, HC) independently reviewed titles and abstracts obtained from the searches and selected potentially relevant studies. Two review authors (TP, LH) followed the same procedure for this update. We obtained full‐text articles and read them in detail to determine whether they fulfilled inclusion criteria. In the event of any dispute as to whether a study met the inclusion criteria, a discussion between review authors took place. We did not need to refer any disagreement to an independent arbiter. </p> </section> <section id="CD009043-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Both review authors (TP and HC original; TP and LH update) independently extracted data from included studies and entered them onto a pre‐designed data extraction form. We extracted and entered the following data. </p> <p> <ul id="CD009043-list-0005"> <li> <p>Study procedures, including recruitment, diagnosis, medication, dosage, duration and clinical setting. </p> </li> <li> <p>Study design.</p> </li> <li> <p>Method of randomisation.</p> </li> <li> <p>Method of allocation concealment.</p> </li> <li> <p>Blinding of participants, personnel and outcome assessors.</p> </li> <li> <p>Inclusion and exclusion criteria for participants.</p> </li> <li> <p>Number of participants.</p> </li> <li> <p>Age distribution.</p> </li> <li> <p>Gender.</p> </li> <li> <p>Loss to follow‐up.</p> </li> <li> <p>Premature discontinuation and reasons for such.</p> </li> <li> <p>Outcomes.</p> </li> <li> <p>Incomplete outcome data and selective outcome reporting.</p> </li> <li> <p>Method of analysis.</p> </li> <li> <p>Comparability of groups at baseline.</p> </li> </ul> </p> <p>We compared extracted data to ensure accuracy, and we resolved discrepancies through discussion between review authors. One review author (TP) entered data into Review Manager (<a href="./references#CD009043-bbs2-0052" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>), and the other (LH) checked the data for accuracy. </p> </section> <section id="CD009043-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (original review: TP and HC; this update: TP and LH) independently assessed the risk of bias of each included study according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009043-bbs2-0041" title="HigginsJPT , AltmanDG , Sterne J on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org. ">Higgins 2011a</a>). Review authors assessed each included study against the seven domains described below and assigned a rating of low risk of bias, high risk of bias or unclear risk of bias (uncertain risk of bias). When risk of bias was unclear, we sought additional information from the study authors. When the two review authors disagreed, we consulted the original paper until we were able to make a decision. </p> <section id="CD009043-sec-0046"> <h5 class="title">Random sequence generation</h5> <p>Description: The method by which participants were randomly allocated to different intervention groups is described in sufficient detail as to determine whether comparable groups were produced. </p> <p>Review authors’ judgement: Was the allocation sequence adequately generated?</p> </section> <section id="CD009043-sec-0047"> <h5 class="title">Allocation concealment</h5> <p>Description: The method by which participants were notified of intervention schedules is described in sufficient detail to assess whether such schedules could be foreseen in advance of, or during, recruitment. </p> <p>Review authors’ judgement: Was allocation adequately concealed?</p> </section> <section id="CD009043-sec-0048"> <h5 class="title">Blinding of participants and personnel</h5> <p>Description: Any measures taken to blind participants and personnel were described in sufficient detail to determine whether knowledge of intervention type was revealed at any point during the study. </p> <p>Review authors’ judgement: Was blinding adequate during the study?</p> </section> <section id="CD009043-sec-0049"> <h5 class="title">Blinding of outcome assessment</h5> <p>Description: Any measures taken to blind outcome assessors were described in sufficient detail to determine whether knowledge of intervention type was revealed at any point during the study. </p> <p>Review authors’ judgement: Was blinding adequate during the study?</p> </section> <section id="CD009043-sec-0050"> <h5 class="title">Incomplete outcome data</h5> <p>Description: Intention‐to‐treat analysis (analysis comparing participants in the groups to which they were originally randomly assigned versus complete outcome data available for all randomised participants) was included in each study. Review authors extracted and reported data on the distribution across intervention groups, on attrition and exclusion, on reasons for missed outcomes and on re‐inclusion in analyses.  </p> <p>Review authors’ judgement: Were incomplete study data dealt with adequately by study authors? </p> </section> <section id="CD009043-sec-0051"> <h5 class="title">Selective outcome reporting</h5> <p>Description: We attempted to assess the possibility of selective outcome reporting by study authors. We checked study protocols through trial registries and compared outcomes listed in the protocol versus the published report. We then compared outcomes listed in the methods section of the manuscript versus those those listed in the results section. We also assessed and reported which studies collected data on a small number of key outcomes that are routinely measured. </p> <p>Review authors’ judgement: Are included studies free of any possibility of selective outcome reporting? </p> </section> <section id="CD009043-sec-0052"> <h5 class="title">Other sources of bias</h5> <p>Description: We investigated any possibility of potential threats to validity in the included studies. Possible sources included: </p> <p> <ul id="CD009043-list-0006"> <li> <p>design‐specific risk of bias;</p> </li> <li> <p>early stopping;</p> </li> <li> <p>baseline imbalance;</p> </li> <li> <p>inappropriate administration of a co‐intervention; and</p> </li> <li> <p>use of an insensitive instrument to measure outcomes.</p> </li> </ul> </p> <p>Review authors’ judgement: Are included studies free of other problems that could put the investigation at high risk of bias? </p> </section> </section> <section id="CD009043-sec-0053"> <h4 class="title">Measures of treatment effect</h4> <section id="CD009043-sec-0054"> <h5 class="title">Binary data</h5> <p>We used risk ratio (RR) estimations with 95% CIs for binary outcomes. </p> </section> <section id="CD009043-sec-0055"> <h5 class="title">Continuous data</h5> <p>For continuous outcomes, we used the mean difference (MD) to pool outcomes measured on the same scale across studies. We also performed an intention‐to‐treat analysis and included all randomised participants in the analysis, retained in the groups to which they were allocated. For additional methods to be used in future updates of this review, please see our protocol (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>) and <a href="./appendices#CD009043-sec-0134">Appendix 3</a>. </p> </section> <section id="CD009043-sec-0056"> <h5 class="title">Time‐to‐event data</h5> <p>We used hazard ratio (HR) estimations with 95% CIs for time‐to‐event outcomes.</p> </section> </section> <section id="CD009043-sec-0057"> <h4 class="title">Unit of analysis issues</h4> <p>We did not encounter any unit of analysis issues. Please see our protocol (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>) and <a href="./appendices#CD009043-sec-0134">Appendix 3</a> for methods that we will use to deal with these issues when we update this review. </p> </section> <section id="CD009043-sec-0058"> <h4 class="title">Dealing with missing data</h4> <p>When data were missing, we first attempted to contact the study authors. Neither of the included studies reported standard deviations for data on the Aberrant Behavior Checklist (ABC) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>), the Clinical Global Impression ‐ Severity (CGI‐S) scale (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>) and the Children’s Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS) (<a href="./references#CD009043-bbs2-0037" title="GoodmanWK , PriceLH , RasmussenSA , MazureC , FleischmannRL , HillCL , et al. The Yale‐Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry1989;46(11):1006‐11. [PUBMED: 2684084] ">Goodman 1989</a>). Furthermore, although study authors responded to our requests for further information, they were not able to provide us with the standard deviations that we requested. Correspondence with study authors and a statistician allowed us to use statistical methods, when necessary, to back‐calculate missing data. Therefore, for <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>, we back‐calculated standard deviations from given standard errors. For <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, we back‐calculated standard deviations from given 95% CIs. We performed back‐calculations using the methods specified in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009043-bbs2-0042" title="HigginsJPT , DeeksJJ , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://handbook.cochrane.org. ">Higgins 2011b</a>). We described missing data and dropouts for each study included in the review in the 'Risk of bias' tables (beneath the <a href="./references#CD009043-sec-0143" title="">Characteristics of included studies</a> tables). </p> </section> <section id="CD009043-sec-0059"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed methodological heterogeneity by comparing trial designs, and clinical heterogeneity by comparing the distribution of important participant factors such as age. We estimated heterogeneity through the DerSimonian and Laird method. We then assessed statistical heterogeneity by examining the I² statistic, an approximate quantity that describes the proportion of variation in point estimates that is due to heterogeneity of studies rather than to sampling error. In addition, we performed a Chi² test of homogeneity to determine the strength of evidence that heterogeneity is genuine. We examined I² and Chi² statistics in conjunction with one another because of the limitations of each statistic independently, especially considering the small number of studies included in this review. We used a significance level of 0.10 for the Chi² test. We also described tau², an estimate of between‐study variability, when presenting results of the random‐effects model. </p> </section> <section id="CD009043-sec-0060"> <h4 class="title">Assessment of reporting biases</h4> <p>As we found only three studies, we did not assess reporting bias. See our protocol (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>) and <a href="./appendices#CD009043-sec-0134">Appendix 3</a> for methods to be used for future updates of this review. </p> </section> <section id="CD009043-sec-0061"> <h4 class="title">Data synthesis</h4> <p>We performed a meta‐analysis of the data, using both fixed‐effect and random‐effects models, which we compared to assess statistical heterogeneity. We used Mantel‐Haenszel methods for RRs because of the rarity of these events, as the Mantel‐Haenszel weighting scheme is preferable with sparse data (<a href="./references#CD009043-bbs2-0043" title="DeeksJJ , HigginsJPT , Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011c</a>). We analysed time‐to‐event data and MDs using inverse variance methods. We did not plan to combine trials with important differences in methods, inclusion criteria, participants and administration of medication (e.g. trials with only adult participants would not be combined with trials of only children; trials lasting two weeks would not be combined with trials lasting one year). When we were unable to perform a meta‐analysis, we described trial data with respect to the review's primary and secondary outcomes. When significant heterogeneity was present in the fixed‐effect model, we presented results from the random‐effects model. </p> <section id="CD009043-sec-0062"> <h5 class="title">Summary of findings</h5> <p>We created a 'Summary of findings' table, which includes the effect estimate, 95% CIs, number of participants and quality of evidence for major outcomes included in the review (ABC ‐ Irritability subscale, ABC ‐ Hyperactivity subscale, ABC ‐ Stereotypy subscale, weight gain, sedation, tremor, relapse rate). We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) method to assess the quality of the body of evidence for each outcome (<a href="./references#CD009043-bbs2-0040" title="GuyattG , OxmanAD , AkiEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction ‐ GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383‐94. ">Guyatt 2011</a>). Although we considered RCTs to provide high‐quality evidence, we downgraded the level of evidence to moderate for all outcomes because of the presence of limitations in the design of available studies, and the overall small number of studies in this area. It is thus likely that further research could have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </section> </section> <section id="CD009043-sec-0063"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>As we found only two studies, we did not perform a subgroup analysis. See our protocol (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>) and <a href="./appendices#CD009043-sec-0134">Appendix 3</a> for methods to be used for future updates of this review. </p> </section> <section id="CD009043-sec-0064"> <h4 class="title">Sensitivity analysis</h4> <p>As we found only two studies, we did not perform a sensitivity analysis. See our protocol (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>) and <a href="./appendices#CD009043-sec-0134">Appendix 3</a> for methods to be used for future updates of this review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009043-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009043-sec-0065"></div> <section id="CD009043-sec-0066"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD009043-sec-0143" title="">Characteristics of included studies</a> and <a href="./references#CD009043-sec-0144" title="">Characteristics of excluded studies</a>. </p> <section id="CD009043-sec-0067"> <h4 class="title">Results of the search</h4> <p>In 2011, we found 1569 records, discarded the duplicates and screened 1323 titles and abstracts. We obtained and reviewed 14 full‐text reports. Two studies fitted our inclusion criteria of being randomised, placebo‐controlled, and double‐blinded trials (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>). We excluded the remaining 12 studies because they were review articles, pooled analyses, open‐label retrospective studies or case series studies (<a href="./references#CD009043-bbs2-0064" title="ChingH , PringsheimT . Aripiprazole for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD009043.pub2] ">Ching 2012</a>).  </p> <p>For this update, we ran searches in November 2014 and found 468 records. From these, we reviewed eight full‐text reports. We excluded seven of the eight studies (see <a href="#CD009043-sec-0080">Excluded studies</a>) and included data from one new study in the update of this review (see <a href="#CD009043-fig-0001">Figure 1</a>). The included study was an RCT investigating the safety and efficacy of long‐term maintenance treatment with aripiprazole in ASD (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>). We updated the searches again in October 2015. Among the 111 records found, we identified no eligible studies. </p> <div class="figure" id="CD009043-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD009043-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We found no cluster‐randomised or cross‐over trials. Also, no studies conducted repeated observations on participants. </p> </section> <section id="CD009043-sec-0068"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD009043-sec-0143" title="">Characteristics of included studies</a> tables. </p> <p>Two studies included within this review were described as randomised, placebo‐controlled, double‐blinded trials; each lasted eight weeks (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>). The third study was a randomised, placebo‐controlled, double‐blinded relapse prevention trial, which included two phases (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>). Phase one ‐ the stabilisation phase ‐ consisted of 13 to 26 weeks of single‐blind aripiprazole, and phase two ‐ the randomisation phase ‐ consisted of up to 16 weeks of double‐blinded treatment with aripiprazole or placebo. Participants whose symptoms of irritability demonstrated a stable response to aripiprazole therapy for 12 consecutive weeks in phase one were eligible for randomisation into phase two. </p> <section id="CD009043-sec-0069"> <h5 class="title">Study location</h5> <p>All three studies were multi‐centre studies conducted in the United States (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>). </p> </section> <section id="CD009043-sec-0070"> <h5 class="title">Study participants</h5> <p>All participants in the studies were individuals (children or young people) younger than 18 years of age (age range six to 17 years) (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>). Although the search was not restricted to children/adolescents, results of the search yielded appropriate studies involving only children/adolescents. Every child/adolescent had been diagnosed with autistic disorder. Both boys and girls were included and the number of children/adolescents ranged from 85 (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>) to 218 (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>).  </p> </section> <section id="CD009043-sec-0071"> <h5 class="title">Study interventions and dosage</h5> <p>The intervention used was aripiprazole in several doses, ranging from 2 mg to 15 mg per day. In the <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> study, during phase one ‐ the stabilisation phase ‐ aripiprazole was flexibly dosed between 2 mg and 15 mg per day. During phase two ‐ the randomisation phase ‐ children/adolescents randomised to aripiprazole continued at the dose prescribed at the end of phase one. </p> </section> <section id="CD009043-sec-0072"> <h5 class="title">Study outcomes</h5> <section id="CD009043-sec-0073"> <h6 class="title">Primary outcomes</h6> <section id="CD009043-sec-0074"> <p><b>Emotional and behavioural symptoms</b></p> <p>All three studies used the Aberrant Behaviour Checklist (ABC) to assess five categories of emotional and behavioural symptoms of ASD, notably, irritability, hyperactivity, stereotypy, inappropriate speech and lethargy/withdrawal. The ABC, developed by <a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>, consists of 58 items, organised within five subscales: irritability, hyperactivity, stereotypy, inappropriate speech and withdrawal/lethargy. Each item is scored on a scale from zero (not a problem) to three (severe). In interpreting results of this scale, a decreased score correlates with an improvement in the category, and an increased score correlates with a decline in that category. For example, the highest possible number of points for the irritability subscale is 45 (15 items × three points) and would depict the most severe case. </p> <p>Studies by <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> used the illness severity and global improvement subscales of the Clinical Global Impression (CGI) scale (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>) to measure clinical improvement. Illness severity is rated from one through seven, with one indicating normal, four moderately ill and seven most severely ill. Thus, a decrease in score for CGI‐S (severity) marks an improvement in disease state. Global improvement (illness change) is also rated from one through seven, with one meaning very much improved, four meaning no change and seven meaning very much worse. Thus, a decrease in score for CGI‐C (change) also marks an improvement in disease state. </p> <p>The <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> relapse prevention trial evaluated time from randomisation to relapse of behavioural symptoms. Relapse was defined in one of the following ways. </p> <p> <ul id="CD009043-list-0007"> <li> <p>Aberrant Behavior Checklist ‐ irritability (ABC‐I) score increase &gt; 25% compared with end‐of‐phase one score, and Clinical Global Impressions ‐ Improvement (CGI‐I) rating of “much worse” or “very much worse” relative to the end of phase one, for two consecutive visits. </p> </li> <li> <p>ABC‐I and CGI‐I scores as per definition above at one visit, plus “lost‐to‐follow‐up” at the next visit. </p> </li> <li> <p>ABC‐I and CGI‐I scores as per definition above at one visit, plus initiation of a prohibited drug to treat worsening symptoms of irritability associated with autistic disorder at the next visit. </p> </li> <li> <p>Child discontinued because of hospitalisation for worsening symptoms of irritability associated with autistic disorder or because of lack of efficacy based on the investigator's assessment. </p> </li> </ul> </p> </section> <section id="CD009043-sec-0075"> <p><b>Extrapyramidal side effects</b></p> <p>All three studies used the Simpson Angus Scale (SAS) (<a href="./references#CD009043-bbs2-0056" title="SimpsonGM , AgnusJWS . A ratings scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;45(S212):11‐9. ">Simpson 1970</a>), the Abnormal Involuntary Movement Scale (AIMS) (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>) and the Barnes Akathisia Scale (BARS) (<a href="./references#CD009043-bbs2-0025" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. [PUBMED: 2574607] ">Barnes 1989</a>) to measure extrapyramidal symptoms. </p> </section> </section> <section id="CD009043-sec-0076"> <h6 class="title">Secondary outcomes</h6> <section id="CD009043-sec-0077"> <p><b>Obsessive‐compulsive behaviours</b></p> <p>Both <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> used the Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS) (<a href="./references#CD009043-bbs2-0053" title="ScahillL , RiddleM , McSwiggin‐HardinM , OrtSI , KingRA , GoodmanWK , et al. Children's Yale‐Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):844‐52. [PUBMED: 9183141] ">Scahill 1997</a>) to assess obsessive‐compulsive behaviours. The CY‐BOCS is an adapted version of the Yale‐Brown Obsessive Compulsive Scale (<a href="./references#CD009043-bbs2-0037" title="GoodmanWK , PriceLH , RasmussenSA , MazureC , FleischmannRL , HillCL , et al. The Yale‐Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry1989;46(11):1006‐11. [PUBMED: 2684084] ">Goodman 1989</a>). It requires two informants ‐ child and parent ‐ to rate 10 items on a scale of zero to four. In general, a score of zero on each item shows no symptoms, and a score of four shows extreme symptoms (<a href="./references#CD009043-bbs2-0053" title="ScahillL , RiddleM , McSwiggin‐HardinM , OrtSI , KingRA , GoodmanWK , et al. Children's Yale‐Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):844‐52. [PUBMED: 9183141] ">Scahill 1997</a>); the total maximum score is 40. Therefore, as a higher number corresponds with greater severity of illness, a decrease in mean score on this particular scale shows improvement in symptoms. Both trials looked at the MD in scores between aripiprazole and placebo on these outcome scales. </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> did not provide data related to this outcome. </p> </section> <section id="CD009043-sec-0078"> <p><b>Weight gain and metabolic side effects</b></p> <p>The three studies also reported data on weight gain. As weight gain is a common occurrence for patients taking antipsychotic medications, more than one way of looking at this outcome was presented. Absolute weight gain in kilograms (kg) was presented in all studies, in addition to change in body mass index (BMI). Clinically relevant weight gain was defined in studies as an increase in weight of 7% or more of baseline body weight. </p> </section> <section id="CD009043-sec-0079"> <p><b>Other side effects</b></p> <p>All three studies measured cholesterol, triglycerides and blood sugar. Studies also measured other side effects, including sedation, drooling and tremor. </p> </section> </section> </section> </section> <section id="CD009043-sec-0080"> <h4 class="title">Excluded studies</h4> <p>Overall, we excluded 19 out of 22 studies.</p> <p>In the original review, we excluded 12 of 14 studies because they were review articles, pooled analyses, open‐label retrospective studies or case series studies (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>). </p> <p>In this updated review, we excluded seven of eight studies: two because they used unblinded, non‐randomised, controlled study designs (<a href="./references#CD009043-bbs2-0007" title="D'AlessandroTMM . Low‐dose Abilify and the Treatment of Disruptive Behaviours in Children with Autism Spectrum Disorders [PhD thesis]. Florida: University of Florida, 2012. ">D'Alessandro 2012</a>, <a href="./references#CD009043-bbs2-0014" title="MaloneyA , MickEO , FrazierJ . Aripiprazole decreases irritability in 12 out of 14 youth with autism spectrum disorder. Journal of Child and Adolescent Psychopharmacology2014;24(6):357‐9. ">Maloney 2014</a>), three because they were review articles or pooled analyses of the <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> studies (<a href="./references#CD009043-bbs2-0005" title="BentonT . Aripiprazole to treat irritability associated with autism: a placebo‐controlled, fixed‐dose trial. Current Psychiatry Reports2011;13(2):77‐9. [DOI: 10.1007/s11920‐010‐0172‐0] ">Benton 2011</a>; <a href="./references#CD009043-bbs2-0008" title="Douglas‐HallP , CurranS , BirdV , TaylorD . Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6‐17. Journal of Central Nervous System Disease2011;3:143‐53. [DOI: 10.4137/JCNSD.S4140] ">Douglas‐Hall 2011</a>; <a href="./references#CD009043-bbs2-0017" title="RobbA , AnderssonC , BellocchioEE , ManosG , Rojas‐FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6‐17 years): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):e1‐9. [PUBMED: 21731831] ">Robb 2011</a>), one randomised trial because it did not include a placebo control (<a href="./references#CD009043-bbs2-0011" title="GhanizadehA , SahraeizadehA , BerkM . A head‐to‐head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185‐92. [PUBMED: 23801256] ">Ghanizadeh 2014</a>) and one study because it provided quality of life data (<a href="./references#CD009043-bbs2-0020" title="Varni , JW , Handen , BL , Corey‐LisleP , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/d on health‐related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two randomized controlled trials. Clinical Therapeutics2012;34(4):982‐92. [PUBMED: 22444782] ">Varni 2012</a>) from the two original studies included in our review (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>); however, this was not an outcome of interest in our review. Two of these studies were also excluded from the previous version of this review (<a href="./references#CD009043-bbs2-0005" title="BentonT . Aripiprazole to treat irritability associated with autism: a placebo‐controlled, fixed‐dose trial. Current Psychiatry Reports2011;13(2):77‐9. [DOI: 10.1007/s11920‐010‐0172‐0] ">Benton 2011</a>; <a href="./references#CD009043-bbs2-0017" title="RobbA , AnderssonC , BellocchioEE , ManosG , Rojas‐FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6‐17 years): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):e1‐9. [PUBMED: 21731831] ">Robb 2011</a>). </p> </section> </section> <section id="CD009043-sec-0081"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD009043-fig-0002">Figure 2</a> and 'Risk of bias' tables beneath the <a href="./references#CD009043-sec-0143" title="">Characteristics of included studies</a> tables. </p> <div class="figure" id="CD009043-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009043-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD009043-sec-0082"> <h4 class="title">Allocation</h4> <section id="CD009043-sec-0083"> <h5 class="title">Random sequence generation</h5> <p>In <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>, eligible children/adolescents were randomly assigned (1:1) to placebo or aripiprazole (continued at the dose prescribed), but the randomisation sequence generation was not described in the manuscript. In <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>, children/adolescents were randomised to receive placebo or aripiprazole (5, 10 or 15 mg/d) in a 1:1:1:1 ratio, but the randomisation sequence generation was not described in the manuscript. We emailed each of the study authors for clarification but received no response. Consequently, we rated both of these studies as having unclear risk of selection bias. In <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, eligible children/adolescents were randomly assigned (1:1) to flexibly dosed aripiprazole or placebo according to a computer‐generated randomisation schedule prepared by Bristol‐Myers Squibb, using a permuted block design. We rated this study as having low risk of bias. </p> </section> <section id="CD009043-sec-0084"> <h5 class="title">Allocation concealment</h5> <p>In <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>, investigational sites accessed a centralised, call‐in system for randomisation. In <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, investigational sites accessed a call‐in, interactive voice response system when children/adolescents were ready to be randomly assigned. This system assigned a medication bottle number to each child/adolescent. We rated both of these studies as having low risk of bias in this domain. However, in <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>, allocation concealment was not described; thus it is unclear whether knowledge of assignment was adequately prevented. </p> </section> </section> <section id="CD009043-sec-0085"> <h4 class="title">Blinding</h4> <section id="CD009043-sec-0086"> <h5 class="title">Performance bias</h5> <p>In all studies, children/adolescents were reported to be blinded to intervention type. We rated both <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> as having low risk of bias. For <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>, a double‐blind trial was described, but the study did not describe assurance of blinding, and so we rated this study as having unclear risk of bias. </p> </section> <section id="CD009043-sec-0087"> <h5 class="title">Detection bias</h5> <p>In all studies, outcome assessors were reported to be blinded to intervention type. We rated both <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> as having low risk of bias. For <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>, a double‐blind trial was described, but the study did not describe assurance of blinding, and so we rated this study as having unclear risk of bias. </p> </section> </section> <section id="CD009043-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>All studies gave details of attrition. Intention‐to‐treat analyses were performed in all three studies. Below, we describe missing data and dropouts for each study included in the review. </p> <p>In <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>, 19 out of 44 children/adolescents completed the placebo arm of the trial. Twenty‐five discontinued ‐ 23 because of lack of efficacy. Out of 41 children/adolescents, 22 completed the aripiprazole arm of the trial. Nineteen discontinued, 13 because of lack of efficacy, five withdrew consent and one was lost to follow‐up. We rated this study as having high risk of attrition bias. All study participants were included in the analysis of effect. If a participant dropped out of the study, investigators used the last observation carried forward (LOCF) method. </p> <p>In <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>, 38 out of 52 children/adolescents completed the placebo arm of the trial. Fourteen discontinued for various reasons: lack of efficacy (n = 3), side effects (n = 4), withdrawal of consent (n = 2), loss to follow‐up (n = 3), non‐compliance (n = 1) and no longer meeting study criteria (n = 1). Out of 164, 140 children/adolescents completed the aripiprazole arm of the trial, whether 5 mg, 10 mg or 15 mg/d. In total, 26 discontinued for various reasons: side effects (n = 17), withdrawal of consent (n = 3), loss to follow‐up (n = 2), non‐compliance (n = 3) and other (n = 1). None discontinued because of lack of efficacy. The safety sample included all children/adolescents who took at least one dose of study medication, whereas the efficacy sample included all children/adolescents who had at least one post‐randomisation efficacy evaluation performed and compared with baseline values. Study authors performed a LOCF analysis for any child who discontinued. Despite the slightly higher percentage of dropouts in the aripiprazole arm, we rated this study as having low risk of attrition bias, as discontinuations due to side effects were generally higher in active treatment groups compared with placebo groups.   </p> <p>In <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, 36 out of 51 children/adolescents completed the placebo arm of the trial. Fifteen discontinued for various reasons: lack of efficacy (n = 6), side effects (n = 3), withdrawal of consent (n = 2) and loss to follow‐up (n = 4). Thirty‐nine out of 47 children/adolescents finished the aripiprazole arm of the trial. Eight discontinued for various reasons: lack of efficacy (n = 1), side effects (n = 5), withdrawal of consent (n = 1) and loss to follow‐up (n = 1). The safety sample included all but one child who was lost to follow‐up before entering the intervention phase. In the efficacy sample, two children were excluded (withdrawal of consent and side effects), as they did not complete a post‐baseline efficacy evaluation. We rated this study as having low risk of attrition bias. </p> </section> <section id="CD009043-sec-0089"> <h4 class="title">Selective reporting</h4> <p>All three studies pre‐specified primary and secondary outcomes and reported expected measures of outcomes. Study protocols are available online at <a href="http://www.clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> (<a href="https://clinicaltrials.gov/ct2/show/NCT00332241" target="_blank">NCT00332241</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT00337571" target="_blank">NCT00337571</a>, <a href="https://clinicaltrials.gov/ct2/show/NCT01227668" target="_blank">NCT01227668</a>); thus, we judged these studies to be at low risk of selective reporting bias. </p> <p>Please see our protocol (<a href="./references#CD009043-bbs2-0063" title="ChingH , PringsheimT . Aripiprazole for Autism Spectrum Disorders (ASD). Cochrane Database of Systematic Reviews2011, Issue 3. [DOI: 10.1002/14651858.CD009043] ">Ching 2011</a>) and <a href="./appendices#CD009043-sec-0134">Appendix 3</a> for additional methods that we would have used to assess small‐study effects had we identified 10 or more studies. </p> </section> <section id="CD009043-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <p>Although all three studies received funding from pharmaceutical companies, we did not judge this to be a matter of concern and thus rated all three studies as having low risk of bias. </p> </section> </section> <section id="CD009043-sec-0091"> <h3 class="title" id="CD009043-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD009043-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <p>We were able to perform a meta‐analysis of data from <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, as no important clinical heterogeneity was found. Furthermore, because both trials used the same measures and reported changes in scores and endpoint data in the same way, we were able to perform meta‐analyses for most of the outcomes listed below. The <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> trial had important differences in methods; therefore, we have described the results of this trial separately. For the study by <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>, if a participant dropped out of the study, investigators used the LOCF method for their analysis. </p> <p>We used both fixed‐effect and random‐effects models, which we then compared to assess statistical heterogeneity. Random‐effects and fixed‐effect models yielded nearly identical results in all analyses performed, with no difference greater than 0.1 point for any measure. Below, we present results from random‐effects models. </p> <p>Minimal clinically important differences are not listed, as they are difficult to define because they vary depending on who is making the judgement and how severe underlying symptoms are determined to be. Thus, when combined with variation in our estimates (95% CIs), these differences will not lead to an accurate interpretation of study results. Instead, we have given information about the rating scales used, including maximum number of points possible, so that clinicians can make their own judgement as to whether the amount of change seen is clinically important. </p> <section id="CD009043-sec-0092"> <h4 class="title">Primary outcomes</h4> <section id="CD009043-sec-0093"> <h5 class="title">Emotional and behavioral symptoms</h5> <section id="CD009043-sec-0094"> <h6 class="title">Irritability</h6> <p>All three studies (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) assessed irritability using the ABC ‐ Irritability subscale (15 items yielding a maximum of 45 points) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>). </p> <p>A meta‐analysis of two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) yielded an MD of ‐6.17 points (change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐9.07 to ‐3.26, tau² = 1.47, I² = 33%, P value &lt; 0.00001, 308 children/adolescents, moderate‐quality evidence; <a href="./references#CD009043-fig-0003" title="">Analysis 1.1</a>). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> found no differences in scores between children/adolescents treated with aripiprazole and those treated with placebo from the end of phase one to week 16 of phase two. </p> </section> <section id="CD009043-sec-0095"> <h6 class="title">Hyperactivity</h6> <p>All three studies (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) assessed hyperactivity using the ABC ‐ Hyperactivity subscale (16 items yielding a maximum of 48 points) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>). </p> <p>A meta‐analysis of two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) yielded an MD of ‐7.93 points (change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐10.98 to ‐4.88, tau² = 2.27, I² = 44%, P value &lt; 0.00001, 308 children/adolescents, moderate‐quality evidence; <a href="./references#CD009043-fig-0004" title="">Analysis 1.2</a>). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> reported differences in scores between children/adolescents treated with aripiprazole and those treated with placebo (MD ‐5.2, 95% CI ‐10.2 to ‐0.2, P value = 0.041, 85 children/adolescents). </p> </section> <section id="CD009043-sec-0096"> <h6 class="title">Stereotypy</h6> <p>All three studies (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) assessed stereotypy using the ABC ‐ Stereotypy subscale (seven items yielding a maximum 21 points) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>). </p> <p>A meta‐analysis of two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) yielded an MD of ‐2.66 points (change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐3.55 to ‐1.77, tau² = 0.00, I² = 0%, P value &lt; 0.00001, 308 children/adolescents, moderate‐quality evidence; <a href="./references#CD009043-fig-0005" title="">Analysis 1.3</a>). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> reported differences in scores between children/adolescents treated with aripiprazole and those treated with placebo (MD ‐2.0, 95% CI ‐3.70 to ‐0.40, P value = 0.018, 85 children/adolescents). </p> </section> <section id="CD009043-sec-0097"> <h6 class="title">Inappropriate speech</h6> <p>All three studies (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) assessed inappropriate speech using the ABC ‐ Inappropriate Speech subscale (four items yielding a maximum 12 points) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>). </p> <p>A meta‐analysis of two studies yielded an MD of ‐1.43 points (change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐2.60 to ‐0.27, tau² = 0.51, I² = 71%, P value = 0.02, 308 children/adolescents; <a href="./references#CD009043-fig-0006" title="">Analysis 1.4</a>). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> reported differences in scores between children/adolescents treated with aripiprazole and those treated with placebo (MD ‐1.5, 95% CI ‐2.6, ‐0.3, P value = 0.013). </p> </section> <section id="CD009043-sec-0098"> <h6 class="title">Lethargy/withdrawal</h6> <p><a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> assessed lethargy/withdrawal using the lethargy/withdrawal subscale of the ABC (16 items yielding a maximum of 48 points) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>). We combined these studies in a meta‐analysis. Results yielded an MD of ‐1.19 points (change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐2.77 to 0.40, tau² = 0.00, I² = 0%, P value = 0.14, 308 children/adolescents; <a href="./references#CD009043-fig-0007" title="">Analysis 1.5</a>). </p> </section> <section id="CD009043-sec-0099"> <h6 class="title">Aggression</h6> <p>No studies provided data on this outcome.</p> </section> <section id="CD009043-sec-0100"> <h6 class="title">Clinical improvement</h6> <p>All three studies (<a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>; <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) assessed severity using the CGI‐S subscale (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>). A meta‐analysis of two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) found an MD of ‐0.57 point (mean change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐0.96 to ‐0.18, tau² = 0.05, I² = 63%, P value = 0.004, 308 children/adolescents; <a href="./references#CD009043-fig-0008" title="">Analysis 1.6</a>). <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> found no differences in scores between children treated with aripiprazole and those treated with placebo from the end of phase one to week 16 of phase two. </p> <p>Two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) assessed clinical improvement using the CGI‐I subscale (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>). A meta‐analysis of these studies yielded an MD of ‐1.33 points between aripiprazole and placebo, which approximates a one‐point change on the scale (of one to seven), in favour of aripiprazole (95% CI ‐1.75 to ‐0.92, tau² = 0.00, I² = 0%, P value &lt; 0.00001, 308 children/adolescents; <a href="./references#CD009043-fig-0009" title="">Analysis 1.7</a>). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> reported no differences between aripiprazole and placebo for the primary endpoint ‐ time from randomisation to relapse (P value = 0.097). Kaplan‐Meier relapse rates at week 16 were 35% for aripiprazole and 52% for placebo, for a hazard ratio (aripiprazole/placebo) of 0.57 (95% CI 0.28 to 1.12, low‐quality evidence). A treatment‐by‐race interaction was explored and was found (P value = 0.034). Among white children/adolescents (n = 59), aripiprazole treatment resulted in a lower relapse rate (25.8%) than placebo (60.7%), with a hazard ratio of 0.33 (95% CI 0.14 to 0.78, P value = 0.011), whereas among non‐white children/adolescents (n = 26), the two treatment arms did not differ. An age‐interaction test found no evidence of an age interaction. </p> </section> </section> <section id="CD009043-sec-0101"> <h5 class="title">Extrapyramidal side effects</h5> <p>Extrapyramidal side effects are adverse, movement‐related symptoms, which include drug‐induced parkinsonism, dystonia, akathisia and tardive dyskinesia. </p> <p>A meta‐analysis of two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) found no difference in rates of extrapyramidal symptom events among children/adolescents treated with aripiprazole compared with placebo (RR 1.89, 95% CI 0.98 to 3.66, tau² = 0.00, I² = 0%, P value = 0.06, 313 children/adolescents; <a href="./references#CD009043-fig-0010" title="">Analysis 1.8</a>). The result may not have reached statistical significance because the analysis lacked power with only two included studies. We were not able to perform a meta‐analysis on extrapyramidal side effects, as neither study provided standard deviations, standard errors or CIs for data from SAS (<a href="./references#CD009043-bbs2-0056" title="SimpsonGM , AgnusJWS . A ratings scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica1970;45(S212):11‐9. ">Simpson 1970</a>), AIMS (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>) and BARS (<a href="./references#CD009043-bbs2-0025" title="BarnesTR . A rating scale for drug‐induced akathisia. British Journal of Psychiatry1989;154:672‐6. [PUBMED: 2574607] ">Barnes 1989</a>). <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> did not find differences between intervention groups with respect to mean change from baseline on these three measures. <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> reported no differences between placebo‐ and aripiprazole‐treated children/adolescents in the mean change from baseline on BARS. On SAS, children/adolescents treated with a 10 mg dose of aripiprazole had significantly greater change from baseline (+ 0.7) compared with placebo‐treated children/adolescents (‐0.4) (P value = 0.006). <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> also reported a significant change from baseline on the AIMS in all aripiprazole‐treated children/adolescents compared with placebo‐treated children/adolescents. Children/adolescents taking aripiprazole showed a decrease in scores (‐0.1 to ‐0.2 points) compared with placebo‐treated children/adolescents, who had an increase in score of 0.2 points (P value &lt; 0.05). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>, in phase one (the single‐blind phase), reported that 27 children/adolescents (17.4%) had treatment‐emergent extrapyramidal symptom‐related side effects. Extrapyramidal symptom‐related side effects occurred in 7.7% of children/adolescents treated with aripiprazole and in 7% of children/adolescents treated with placebo. Investigators reported no differences between groups on SAS, AIMS and BARS. Movement disorders were also common in phase two (5.1% for aripiprazole versus 0% for placebo). </p> </section> </section> <section id="CD009043-sec-0102"> <h4 class="title">Secondary outcomes</h4> <section id="CD009043-sec-0103"> <h5 class="title">Obsessive‐compulsive behaviours</h5> <p>Two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>) used the Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS) (<a href="./references#CD009043-bbs2-0053" title="ScahillL , RiddleM , McSwiggin‐HardinM , OrtSI , KingRA , GoodmanWK , et al. Children's Yale‐Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):844‐52. [PUBMED: 9183141] ">Scahill 1997</a>) to assess obsessive‐compulsive behaviours in 308 children/adolescents. We combined these studies in a meta‐analysis (<a href="./references#CD009043-fig-0011" title="">Analysis 1.9</a>). Results yielded an MD of ‐1.93 points (mean change from baseline) between aripiprazole and placebo, in favour of aripiprazole (95% CI ‐3.86 to 0.00, tau² = 1.65, I² = 84%, P value = 0.05). </p> </section> <section id="CD009043-sec-0104"> <h5 class="title">Weight gain and metabolic side effects</h5> <p>In a meta‐analysis of two studies (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>), the RR of clinically relevant weight gain while taking aripiprazole was approximately 3.78 kg compared with placebo (95% CI 1.78 to 8.02, tau² = 0.00, I² = 0%, P value = 0.0005, 308 children/adolescents; <a href="./references#CD009043-fig-0012" title="">Analysis 1.10</a>). The MD in weight gain between the aripiprazole group and the placebo group was 1.13 kg (95% CI 0.71 to 1.54, tau² = 0.00, I² = 0%, P value &lt; 0.00001, two studies, 308 children/adolescents, moderate‐quality evidence; <a href="./references#CD009043-fig-0013" title="">Analysis 1.11</a>). We noted no difference between study groups as regards change in body mass index (BMI) (MD 0.44, 95% CI ‐0.27 to 1.16, tau² = 0.00, I² = 0%, P value = 0.22, two studies, 313 children/adolescents; <a href="./references#CD009043-fig-0014" title="">Analysis 1.12</a>). Both <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> (313 children/adolescents) reported no differences in rates of abnormal triglycerides between children/adolescents treated with placebo and those treated with aripiprazole (<a href="./references#CD009043-fig-0015" title="">Analysis 1.13</a>), nor in low‐density lipoprotein (<a href="./references#CD009043-fig-0016" title="">Analysis 1.14</a>), high‐density lipoprotein (<a href="./references#CD009043-fig-0017" title="">Analysis 1.15</a>) or blood sugar (<a href="./references#CD009043-fig-0018" title="">Analysis 1.16</a>). </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> reported an increase of 25.2% in weight in phase one (all children/adolescents took aripiprazole during phase one). At week 16 of phase two, children/adolescents treated with aripiprazole gained a mean of 2.2 kg and placebo recipients gained 0.6 kg. Investigators reported no changes on metabolic laboratory tests (cholesterol, triglycerides and glucose) from baseline to week 16, during phase two, between children/adolescents treated with aripiprazole and those treated with placebo. </p> </section> <section id="CD009043-sec-0105"> <h5 class="title">Other side effects</h5> <p>For the two studies included in the meta‐analysis (<a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a>; <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>), we chose clinically relevant effects of concern, such as sedation, drooling and tremor. Such side effects were common in the aripiprazole group. In comparison with the control group, the RR of experiencing sedation was 4.28 times more likely if taking aripiprazole (95% CI 1.58 to 11.60, tau² = 0.00, I² = 0%, P value = 0.004, two studies, 313 children/adolescents, moderate‐quality evidence; <a href="./references#CD009043-fig-0019" title="">Analysis 1.17</a>). A person was 9.64 times more likely to experience drooling if taking aripiprazole (95% CI 1.29 to 72.10, tau² = 0.000, I² = 0%, P value = 0.03, two studies, 313 children/adolescents; <a href="./references#CD009043-fig-0020" title="">Analysis 1.18</a>) and was 10.26 times more likely to experience tremor (95% CI 1.37 to 76.63, tau² = 0.00, I² = 0%, P value = 0.02, two studies, 313 children/adolescents, moderate‐quality evidence; <a href="./references#CD009043-fig-0021" title="">Analysis 1.19</a>) compared with placebo. </p> <p><a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> reported that somnolence (14.8%) and vomiting (14.2%) were common side effects in phase one (all children/adolescents treated with aripiprazole during phase one), and in phase two, the most common side effects with aripiprazole were upper respiratory tract infection (10.3% for aripiprazole versus 2.3% for placebo) and constipation (5.1% for aripiprazole versus 0% for placebo). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009043-sec-0106" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009043-sec-0106"></div> <section id="CD009043-sec-0107"> <h3 class="title" id="CD009043-sec-0107">Summary of main results</h3> <p>Both short‐term studies showed that aripiprazole can improve some symptoms of autism spectrum disorders (ASD). From these results, we can suggest that aripiprazole appears effective for the short‐term medication intervention of children/adolescents with ASD. Several significant results point towards efficacy of aripiprazole as a short‐term medication intervention for children/adolescents with ASD. Most of the primary outcomes specified were significantly better with aripiprazole as compared with placebo intervention. These primary outcomes, as stated earlier in the <a href="#CD009043-sec-0036">Types of outcome measures</a> section, include score changes on the Aberrant Behaviour Checklist (ABC) (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>) and Clinical Global Impression (CGI) scales (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>). </p> <p>Meta‐analysis of mean changes in scores on the ABC ‐ Irritability subscale and the CGI ‐ Improvement scale from both <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> shows efficacy of aripiprazole in treating this behavioural symptom (see <a href="./references#CD009043-fig-0003" title="">Analysis 1.1</a> and <a href="./references#CD009043-fig-0009" title="">Analysis 1.7</a>). Significant improvements also occurred in the hyperactivity and stereotypy subscales of the ABC. Changes on remaining ABC subscales pertaining to social withdrawal and inappropriate speech were not expected, as no evidence suggests that antipsychotic therapy is helpful in treating the core social and communication impairments of ASD. The magnitude of change on the ABC ‐ Irritability subscale was 6.17 points with aripiprazole relative to placebo. With mean baseline scores in the study group ranging from 25 to 30 out of a total of 45 points on this scale, a six‐point reduction in symptoms may be considered clinically meaningful by caregivers. Similarly, for the ABC ‐ Hyperactivity subscale, the magnitude of change was 7.93 points with aripiprazole relative to placebo, with baseline scores in the study group on this subscale ranging from 30 to 35 out of a total of 48 points. This change in hyperactivity score may be clinically meaningful for caregivers. Changes in stereotypy scores were more modest, with a decrease of 2.66 points with aripiprazole relative to placebo. Stereotypy subscale baseline scores ranged from 10 to 12 among study groups at baseline, out of a total of 21 points. </p> <p>Secondary outcomes included results from the Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS) (<a href="./references#CD009043-bbs2-0053" title="ScahillL , RiddleM , McSwiggin‐HardinM , OrtSI , KingRA , GoodmanWK , et al. Children's Yale‐Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):844‐52. [PUBMED: 9183141] ">Scahill 1997</a>), metabolic side effects such as weight gain, extrapyramidal symptoms and other side effects such as sedation, drooling and tremor. We noted no improvement in obsessive‐compulsive behaviours. Multiple children/adolescents in the aripiprazole group experienced side effects compared with those in the placebo group. Evidence was consistent for both an increase and a decrease in extrapyramidal symptoms. Risk of experiencing side effects of sedation, drooling and tremor was higher if treated with aripiprazole. Individuals treated with aripiprazole gained more weight relative to placebo, and clinically significant weight gain was more likely to occur if treated with aripiprazole than placebo. </p> <p>The <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a> relapse prevention trial found no difference between aripiprazole and placebo during maintenance treatment (P value = 0.097). However, evidence showed a treatment‐by‐race relationship (P value = 0.034), wherein white children/adolescents demonstrated lower relapse rates on aripiprazole than placebo, although no difference was noted between non‐white children/adolescents. These results suggest that some children/adolescents may benefit from continued use of aripiprazole, and others may not. For secondary endpoints, the most clinically important effect observed was a deterioration in scores on the ABC ‐ Hyperactivity subscale, among children/adolescents treated with placebo compared with aripiprazole. Greater weight gain and increased movement disorders were associated with continued aripiprazole. In combination with results from <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, it is suggested that children/adolescents taking aripiprazole should be re‐evaluated periodically to determine whether aripiprazole remains appropriate for treatment of ASD symptoms. </p> </section> <section id="CD009043-sec-0108"> <h3 class="title" id="CD009043-sec-0108">Overall completeness and applicability of evidence</h3> <p>Although the two short‐term use studies are complete in their reporting, and provide highly applicable findings, world literature on the use of aripiprazole for ASD is small. Only one long‐term use study has been conducted and is at high risk of bias due to attrition. Short‐term use studies found clinically important moderate improvements in irritability and hyperactivity, and small improvements in stereotypies, with aripiprazole compared with placebo. This review aimed to determine the safety and efficacy of aripiprazole for any ASD, but data were available only on children/adolescents with a diagnosis of autistic disorder, and failed to include those with Asperger's syndrome or pervasive developmental disorders ‐ not otherwise specified (PDD‐NOS), or adults with ASD. Although classification of these disorders changed in 2013, studies included only those at the most severe end of the spectrum. Data from a 14‐week open‐label study of aripiprazole, which was not eligible for inclusion (<a href="./references#CD009043-bbs2-0057" title="StiglerKA , Diener , JT , KohnAE , LiL , EricksonCA , PoseyDJ , et al. Aripiprazole in pervasive development disorder not otherwise specified and Asperger's disorder: a 14‐week, prospective, open‐label study. Journal of Child and Adolescent Psychopharmacology2009;19(3):265‐74. [PUBMED: 19519261] ">Stigler 2009</a>), provided information on participants with Asperger's syndrome and PDD‐NOS and found similar trends of efficacy as the studies included in this review. Furthermore, all included studies were performed in the United States and were sponsored by pharmaceutical companies. </p> <p>No trials examined the specific link between medication and behavioural interventions. Trials that include behavioural interventions and the addition of medication for families in crisis, or with behavioural interventions that are not sufficient, would provide the most applicable evidence related to current guidelines for treatment of ASD. </p> <p>One study, which did not meet our inclusion criteria for the review, provided information on comparative efficacy of aripiprazole. <a href="./references#CD009043-bbs2-0011" title="GhanizadehA , SahraeizadehA , BerkM . A head‐to‐head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry and Human Development2014;45(2):185‐92. [PUBMED: 23801256] ">Ghanizadeh 2014</a> randomised 59 children/adolescents with ASD to risperidone or aripiprazole twice daily. Investigators assessed outcomes using the ABC (<a href="./references#CD009043-bbs2-0021" title="AmanM , SinghN . Aberrant Behaviour Checklist: Manual. New York: Slosson Educational Publications, 1986. ">Aman 1986</a>), the CGI ‐ Improvement scale (<a href="./references#CD009043-bbs2-0039" title="GuyW . Early Clinical Drug Evaluation Unit (ECDEU) Assessment Manual for Psychopharmacology. National Institute Mental Health. Bethesda, MD: National Institute of Mental Health, 1976. ">Guy 1976</a>) and systematic examination for extrapyramidal symptoms and other side effects. Both aripiprazole and risperidone decreased all ABC subscale scores significantly (P value &lt; 0.05), but no significant difference between intervention groups was evident. Researchers also reported no difference between intervention groups on the CGI‐I subscale scores at endpoint. Both interventions were well tolerated, and the most common side effects were increased appetite, drooling and drowsiness. One child from each intervention arm withdrew because of side effects. Therefore, this study found that aripiprazole and risperidone show similar efficacy and side effects for treatment of ASD symptoms in children/adolescents. </p> <p>Another study that did not meet our inclusion criteria for the review provided information on the impact of aripiprazole on quality of life. In a post hoc analysis of data from <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, <a href="./references#CD009043-bbs2-0020" title="Varni , JW , Handen , BL , Corey‐LisleP , GuoZ , ManosG , AmmermanDK , et al. Effect of aripiprazole 2 to 15 mg/d on health‐related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two randomized controlled trials. Clinical Therapeutics2012;34(4):982‐92. [PUBMED: 22444782] ">Varni 2012</a> evaluated the effects of use of aripiprazole in children/adolescents with ASD on health‐related quality of life (HRQoL). A total of 316 children/adolescents were randomised to aripiprazole or placebo and were evaluated at baseline and at eight weeks by means of three Pediatric Quality of Life Inventory (PedsQL) scales (<a href="./references#CD009043-bbs2-0058" title="VarniJW , SeidM , RodeCA . The PedsQL: measurement model for the pediatric quality of life inventory. Medical Care1999;37(2):126‐39. [PUBMED: 10024117] ">Varni 1999</a>). Aripiprazole was associated with greater improvement in the PedsQL combined scale total score (MD 7.8, 95% CI 3.8 to 11.8, P value &lt; 0.001), and in all three PedsQL scales (emotional functioning: MD 7.8, 95% CI 3.4 to 12.2, P value &lt; 0.05; social functioning: MD 6.2, 95% CI 0.7 to 11.8, P value &lt; 0.05; and cognitive functioning: MD 9.3, 95% CI 3.8 to 14.9; P value &lt; 0.05). These findings suggest that short‐term treatment with aripiprazole is associated with increased HRQoL in children/adolescents with ASD. </p> </section> <section id="CD009043-sec-0109"> <h3 class="title" id="CD009043-sec-0109">Quality of the evidence</h3> <p>The quality of studies performed on the use of aripiprazole in ASD was moderate. We rated quality as moderate because of unclear risk of bias for some domains in <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, and because of the overall small number of studies conducted on the use of aripiprazole in ASD. We rated quality of evidence for long‐term trials as low because risk of attrition bias for incomplete outcome data was high in <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>. Further research may have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </section> <section id="CD009043-sec-0110"> <h3 class="title" id="CD009043-sec-0110">Potential biases in the review process</h3> <p>We have no other potential biases to report in the review process. Although we have synthesised all existing RCTs of aripiprazole for the treatment of behavioural symptoms in ASD, it must be recognised that available evidence is limited. </p> </section> <section id="CD009043-sec-0111"> <h3 class="title" id="CD009043-sec-0111">Agreements and disagreements with other studies or reviews</h3> <p>No other formal systematic reviews on use of aripiprazole for the treatment of ASD have been published to our knowledge. A pooled analysis of data on side effects from <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a> has been published (<a href="./references#CD009043-bbs2-0017" title="RobbA , AnderssonC , BellocchioEE , ManosG , Rojas‐FernandezC , MathewS , et al. Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6‐17 years): results from a pooled analysis of 2 studies. Primary Care Companion for CNS Disorders2011;13(1):e1‐9. [PUBMED: 21731831] ">Robb 2011</a>). Results and conclusions of our study with respect to side effects of aripiprazole are similar to those provided by Robb and colleagues. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009043-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD009043-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD009043-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 1 Aberrant Behavior Checklist (ABC) ‐ Irritability subscale: mean score changes." data-id="CD009043-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 1 Aberrant Behavior Checklist (ABC) ‐ Irritability subscale: mean score changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 2 Aberrant Behavior Checklist (ABC) ‐ Hyperactivity subscale: mean score changes." data-id="CD009043-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 2 Aberrant Behavior Checklist (ABC) ‐ Hyperactivity subscale: mean score changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 3 Aberrant Behavior Checklist (ABC) ‐ Stereotypy subscale: mean score changes." data-id="CD009043-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 3 Aberrant Behavior Checklist (ABC) ‐ Stereotypy subscale: mean score changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 4 Aberrant Behavior Checklist (ABC) ‐ Inappropriate Speech subscale: mean score changes." data-id="CD009043-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 4 Aberrant Behavior Checklist (ABC) ‐ Inappropriate Speech subscale: mean score changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 5 Aberrant Behavior Checklist (ABC) ‐ Lethargy/Withdrawal subscale: mean score changes." data-id="CD009043-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 5 Aberrant Behavior Checklist (ABC) ‐ Lethargy/Withdrawal subscale: mean score changes. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 6 Clinical Global Impression (CGI) ‐ Severity subscale: mean scores." data-id="CD009043-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 6 Clinical Global Impression (CGI) ‐ Severity subscale: mean scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 7 Clinical Global Impression (CGI) ‐ Improvement subscale: mean scores." data-id="CD009043-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 7 Clinical Global Impression (CGI) ‐ Improvement subscale: mean scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 8 Any extrapyramidal symptom event (side effect)." data-id="CD009043-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 8 Any extrapyramidal symptom event (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 9 Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS): mean scores." data-id="CD009043-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 9 Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS): mean scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 10 Clinically relevant weight gain (side effect)." data-id="CD009043-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 10 Clinically relevant weight gain (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 11 Weight gain (side effect)." data-id="CD009043-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 11 Weight gain (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 12 Body mass index (BMI) change from baseline (side effect)." data-id="CD009043-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 12 Body mass index (BMI) change from baseline (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 13 Elevated fasting triglycerides at endpoint (side effect)." data-id="CD009043-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 13 Elevated fasting triglycerides at endpoint (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 14 Elevated low‐density lipoprotein at endpoint (side effect)." data-id="CD009043-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 14 Elevated low‐density lipoprotein at endpoint (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 15 Decreased high‐density lipoprotein at endpoint (side effect)." data-id="CD009043-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 15 Decreased high‐density lipoprotein at endpoint (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 16 Elevated fasting blood glucose at endpoint (side effect)." data-id="CD009043-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 16 Elevated fasting blood glucose at endpoint (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 17 Sedation (side effect)." data-id="CD009043-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 17 Sedation (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 18 Drooling (side effect)." data-id="CD009043-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 18 Drooling (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009043-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/urn:x-wiley:14651858:media:CD009043:CD009043-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_t/tCD009043-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 19 Tremor (side effect)." data-id="CD009043-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Aripiprazole versus placebo in randomised controlled trials (RCTs), Outcome 19 Tremor (side effect). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/media/CDSR/CD009043/image_n/nCD009043-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009043-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Aripiprazole compared with placebo for autism spectrum disorders (ASD)*</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Patient or population:</b> children/youth with ASD </p> <p><b>Settings:</b> ambulatory care </p> <p><b>Intervention:</b> aripiprazole </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Effect (95% confidence interval)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Number of participants</b> </p> <p><b>(studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ABC ‐ Irritability subscale</b> </p> <p>Mean score changes</p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐6.17 (‐9.07 to ‐3.26) points relative to placebo, in favour of aripiprazole</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ABC ‐ Hyperactivity subscale</b> </p> <p>Mean score changes</p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐7.93 (‐10.98 to ‐4.88) points relative to placebo, in favour of aripiprazole</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ABC ‐ Stereotypy subscale</b> </p> <p>Mean score changes</p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD ‐2.66 (‐3.55 to ‐1.77) points relative to placebo, in favour of aripiprazole</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Weight gain</b> </p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1.13 (0.71 to 1.54) points relative to placebo</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>308</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sedation</b> </p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 4.28 (1.58 to 11.60)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tremor</b> </p> <p>8 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>RR 10.26 (1.37 to 76.63)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>313</p> <p>(2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate<sup>a</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse rate</b> </p> <p>16 weeks of treatment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>HR 0.57 (0.28 to 1.12)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>85</p> <p>(1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Low<sup>b</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>ABC:</b> Aberrant Behavior Checklist; <b>GRADE:</b> Grades of Recommendation, Assessment, Development and Evaluation; <b>HR:</b> hazard ratio;<b>MD:</b> mean difference; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>Quality was rated as moderate because of unclear risk of bias for some domains in <a href="./references#CD009043-bbs2-0002" title="MarcusRN , OwenR , KameL , ManosG , McQuadeRD , CarsonWH , et al. A placebo‐controlled, fixed‐dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(11):1110‐9. [PUBMED: 19797985] ">Marcus 2009</a> and <a href="./references#CD009043-bbs2-0003" title="OwenR , SikichL , MarcusRN , Corey‐LisleP , ManosG , McQuadeRD , et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics2009;124(6):1533‐40. [PUBMED: 19948625] ">Owen 2009</a>, and because of the overall small number of studies conducted using aripiprazole in ASD.<br/> <sup>b</sup>Quality of evidence for long‐term trials was rated as low because of high risk of attrition bias for incomplete outcome data in <a href="./references#CD009043-bbs2-0001" title="FindlingRL , MankosiR , TimkoK , LearsK , McCartneyT , McQuadeRD , et al. Randomized controlled trial investigating the safety and efficacy of aripiprazole in the long‐term maintenance treatment of pediatric patients with irritability associated with autistic disorder. Journal of Clinical Psychiatry2014;75(1):22‐30. [PUBMED: 24502859] ">Findling 2014</a>. Further research may have an important impact on our confidence in the estimate of effect and may change the estimate. </p> <p>*A small number of studies have evaluated the use of aripiprazole for ASD. Only one study examined aripiprazole at a duration longer than eight weeks. Future trials of aripiprazole in children/adolescents with ASD are likely to impact the estimates found in this review. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/full#CD009043-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009043-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aripiprazole versus placebo in randomised controlled trials (RCTs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Aberrant Behavior Checklist (ABC) ‐ Irritability subscale: mean score changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.17 [‐9.07, ‐3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Aberrant Behavior Checklist (ABC) ‐ Hyperactivity subscale: mean score changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.93 [‐10.98, ‐4.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Aberrant Behavior Checklist (ABC) ‐ Stereotypy subscale: mean score changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.66 [‐3.55, ‐1.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Aberrant Behavior Checklist (ABC) ‐ Inappropriate Speech subscale: mean score changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.43 [‐2.60, ‐0.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Aberrant Behavior Checklist (ABC) ‐ Lethargy/Withdrawal subscale: mean score changes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.19 [‐2.77, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical Global Impression (CGI) ‐ Severity subscale: mean scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.96, ‐0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical Global Impression (CGI) ‐ Improvement subscale: mean scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.33 [‐1.75, ‐0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Any extrapyramidal symptom event (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.89 [0.98, 3.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Children's Yale‐Brown Obsessive Compulsive Scale (CY‐BOCS): mean scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.93 [‐3.86, 0.00]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Clinically relevant weight gain (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.78 [1.78, 8.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Weight gain (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>308</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [0.71, 1.54]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Body mass index (BMI) change from baseline (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.27, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Elevated fasting triglycerides at endpoint (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [0.62, 3.67]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Elevated low‐density lipoprotein at endpoint (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.19 [0.13, 76.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Decreased high‐density lipoprotein at endpoint (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.11, 8.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Elevated fasting blood glucose at endpoint (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [0.08, 32.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Sedation (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.28 [1.58, 11.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Drooling (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.64 [1.29, 72.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Tremor (side effect) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>313</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.26 [1.37, 76.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Aripiprazole versus placebo in randomised controlled trials (RCTs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009043.pub3/references#CD009043-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009043.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009043-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009043-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009043-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009043-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009043-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ta#CD009043-note-0003">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009043-note-0010">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009043\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009043\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009043\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009043\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009043\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=z6k50IFd&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009043.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009043.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009043.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009043.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009043.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714932657"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009043.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714932661"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009043.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7ac28ca59368',t:'MTc0MDcxNDkzMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 